Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3973 Target Snapshot

Fibroblast growth factor receptor 4 · SINGLE PROTEIN · Homo sapiens

3,760Compounds
736Assays
16Approved Drugs
4,902.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Fibroblast growth factor receptor 4 shows clinical signal disease relevance led by cancer. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P22455. Start with cancer, then reuse UniProt P22455 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt P22455 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
cancer

Fibroblast growth factor receptor 4 shows clinical signal disease relevance led by cancer. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with cancer because it currently carries clinical signal support. Linked drugs include FGF401. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Fibroblast growth factor receptor 4 as ChEMBL target CHEMBL3973, mapped to UniProt P22455. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Fibroblast growth factor receptor 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3973
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P22455
Fibroblast growth factor receptor 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Fibroblast growth factor receptor 4 is the right protein anchor across sources, using UniProt P22455 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelFibroblast growth factor receptor 4
UniProt AccessionP22455
Component TypeProtein
Sequence Length802 aa

Fibroblast growth factor receptor 4

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Fibroblast growth factor receptor 4, mapped to UniProt P22455. Sequence length is 802 aa.

Mapped IDP22455
Review nameFibroblast growth factor receptor 4
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Fibroblast growth factor receptor 4 shows clinical signal disease relevance led by cancer. 1 more disease program remain visible in the same review block.

Clinical signal Phase I
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugFGF401
Clinical signal Phase I
hepatocellular carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugFGF401
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with cancer because it currently carries clinical signal support. Linked drugs include FGF401. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

16
Approved
5
Phase III
15
Phase II
7
Phase I
Assay Mix

Activity Type Distribution

IC504,727.0
KI12.0
EC504.0
KD159.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3948579 10.0 IC50 0.1 Preclinical
CHEMBL3912731 9.7 IC50 0.2 Preclinical
CHEMBL3912896 9.7 IC50 0.2 Preclinical
CHEMBL3968338 9.7 IC50 0.2 Preclinical
CHEMBL4786195 9.7 IC50 0.2 Preclinical
CHEMBL5194425 9.6 IC50 0.25 Preclinical
CHEMBL3946444 9.52 IC50 0.3 Preclinical
CHEMBL3938786 9.52 IC50 0.3 Preclinical
CHEMBL3924363 9.52 IC50 0.3 Preclinical
CHEMBL3915180 9.52 IC50 0.3 Preclinical
Distribution

pChEMBL Value Distribution

76
5.0
108
5.5
217
6.0
759
6.5
412
7.0
793
7.5
446
8.0
275
8.5
75
9.0
10
9.5
pChEMBL
Approved Drugs

Approved Drugs

FUTIBATINIB
CHEMBL3701238
Approved 2022
INFIGRATINIB
CHEMBL1852688
Approved 2021
INFIGRATINIB PHOSPHATE
CHEMBL1834657
Approved 2021
PEMIGATINIB
CHEMBL4297522
Approved 2020
ERDAFITINIB
CHEMBL3545376
Approved 2019
BRIGATINIB
CHEMBL3545311
Approved 2017
LENVATINIB
CHEMBL1289601
Approved 2015
NINTEDANIB ESYLATE
CHEMBL3039504
Approved 2014
NINTEDANIB
CHEMBL502835
Approved 2014
CERITINIB
CHEMBL2403108
Approved 2014
PONATINIB
CHEMBL1171837
Approved 2012
Assay Landscape

Assay Landscape

736
Total Assays
2,212
Tested Compounds
1
Assay Types
Binding — 736 assays, 2,212 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 423 1,546 7.4
cell-based format 149 269 7.8
assay format 85 337 7.3
tissue-based format 77 0
organism-based format 2 60 6.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine